摘要
系统性硬化症在临床上较为罕见,也被称为硬皮病,属于免疫性疾病的一种,临床上一般根据患者发病后皮肤损伤情况将系统性硬化症分为局限性系统性硬化症、弥漫性系统性硬化症、重叠综合征、无硬化系统性硬化症、未分化结缔组织疾病。通过分析系统性硬化症患者的主要发病原因探讨其应对的治疗措施。系统性硬化症的发病率容易受环境因素、遗传因素的影响,且引起系统性硬化症的环境因素及遗传因素具有多样性,由于系统性硬化症的发病机制尚不清楚,因此临床上治疗系统性硬化症患者仍然存在较大的困难。目前治疗方向主要包括皮肤病变治疗、系统性硬化症的雷诺现象、系统性硬化症的肺部治疗。
Systemic sclerosis is relatively rare in the clinic and is also called scleroderma.It is a type of immune disease.Clinically,systemic sclerosis is generally divided into localized systemic sclerosis and diffuse systemic sclerosis,overlap syndrome,non-sclerotic systemic sclerosis,undifferentiated connective tissue disease.By analyzing the main causes of systemic sclerosis,the author explore the treatment measures.The results showed the onset of systemic sclerosis is easily affected by environmental factors and genetic factors,and the environmental and genetic factors that cause systemic sclerosis are diverse.Because the pathogenesis of systemic sclerosis is unclear,clinically treated patients still have greater difficulties.The current treatment directions include skin lesion treatment,Raynaud’s phenomenon of systemic sclerosis,and pulmonary treatment of systemic sclerosis.
作者
李小芬
韦夙
王乐
杨有国
莫丽丹
江浩
郑玉萍
廖红丽
LI Xiao-fen;WEI Su;WANG Le;YANG You-guo;MO Li-dan;JIANG Hao;ZHENG Yu-ping;LIAO Hong-li(Department of Rheumatology and Immunology,Liuzhou People's Hospital,Guangxi 545006,China)
出处
《药物生物技术》
CAS
2020年第4期390-392,共3页
Pharmaceutical Biotechnology
关键词
系统性
硬化症
发病因素
硬皮病
治疗进展
相关因素
Systemic
Sclerosis
Pathogenesis
Scleroderma
Treatment progress
Related factors